We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+46.36%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$8.12B
AUM Growth
+$2.18B
Cap. Flow
+$164M
Cap. Flow %
2.02%
Top 10 Hldgs %
63.91%
Holding
78
New
15
Increased
7
Reduced
2
Closed
11

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$98.6M
2
BLTE
Belite Bio
BLTE
+$57.4M
3
RNAM
Avidity Biosciences
RNAM
+$55.6M
4
LBRX
LB Pharmaceuticals
LBRX
+$28.2M
5
MLYS icon
Mineralys Therapeutics
MLYS
+$25.4M

Top Sells

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$92.5M
2
RXST icon
RxSight
RXST
+$48.1M
3
TRML
Tourmaline Bio
TRML
+$40.6M
4
ELVN icon
Enliven Therapeutics
ELVN
+$17M
5
HNGE
Hinge Health
HNGE
+$15.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.83%
2 Financials 0.1%
3 Miscellaneous 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELDN icon
51
Eledon Pharmaceuticals
ELDN
$220M
$9.24M 0.11%
3,566,338
– –
JBIO
52
Jade Biosciences
JBIO
$1.11B
$9.17M 0.11%
1,062,326
– –
SABS icon
53
SAB Biotherapeutics
SABS
$310M
$8.85M 0.11%
+4,401,500
New +$9.95M
INSP icon
54
Inspire Medical Systems
INSP
$2.16B
$8.53M 0.11%
+114,901
New +$11.6M
CTMX icon
55
CytomX Therapeutics
CTMX
$586M
$8.49M 0.1%
2,661,331
– –
AVTX icon
56
Avalo Therapeutics
AVTX
$862M
$8.43M 0.1%
662,968
-270,005
-29% -$2.32M
PCSC
57
DELISTED
Perceptive Capital Solutions
PCSC
$7.95M 0.1%
750,000
– –
SRZN icon
58
Surrozen
SRZN
$209M
$7.76M 0.1%
602,626
– –
WGS icon
59
GeneDx Holdings
WGS
$2.82B
$6.25M 0.08%
58,044
– –
ACET icon
60
Adicet Bio
ACET
$79.7M
$6.11M 0.08%
471,313
– –
NAMSW icon
61
NewAmsterdam Pharma Warrant
NAMSW
$52.3M
$5.7M 0.07%
333,333
– –
EVH icon
62
Evolent Health
EVH
$423M
$4.9M 0.06%
+579,052
New +$5.62M
GKOS icon
63
Glaukos
GKOS
$10.1B
$4.42M 0.05%
+54,180
New +$4.98M
DSGN icon
64
Design Therapeutics
DSGN
$765M
$3.58M 0.04%
+475,699
New +$2.38M
EXAS
65
DELISTED
Exact Sciences
EXAS
$3.01M 0.04%
+54,939
New +$2.75M
IFRX icon
66
InflaRx
IFRX
$298M
$2.64M 0.03%
1,973,233
– –
PGNY icon
67
Progyny
PGNY
$2.13B
$2.08M 0.03%
+96,628
New +$2.2M
ACHC icon
68
Acadia Healthcare
ACHC
$2.55B
– –
-89,262
Closed -$2.03M
DYN icon
69
Dyne Therapeutics
DYN
$3.34B
– –
-9,714,392
Closed -$92.5M
ELVN icon
70
Enliven Therapeutics
ELVN
$3.91B
– –
-848,986
Closed -$17M
RXST icon
71
RxSight
RXST
$234M
– –
-3,702,967
Closed -$48.1M
TARA icon
72
Protara Therapeutics
TARA
$222M
– –
-1,039,295
Closed -$3.15M
TRML
73
DELISTED
Tourmaline Bio
TRML
– –
-2,538,925
Closed -$40.6M
TXG icon
74
10x Genomics
TXG
$9.69B
– –
-475,343
Closed -$5.5M
MBX
75
MBX Biosciences
MBX
$2.94B
– –
-377,841
Closed -$4.31M
1 2
3
4

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, RA Capital Management held 78 positions worth $8.12B, up 37% from $5.94B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

RA Capital Management's Q3 2025 filing shows 15 new, 7 increased, 2 reduced and 11 closed positions. Its largest new stake was Nuvalent: 1,246,456 shares worth $108M. The largest sale was Dyne Therapeutics, an estimated $92.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Miscellaneous.

  • RA Capital Management's largest Q3 2025 buy was Nuvalent: 1,246,456 shares worth $108M.
  • RA Capital Management added most to Avidity Biosciences in Q3 2025, an estimated $55.6M increase.
  • RA Capital Management's biggest Q3 2025 reduction was Avalo Therapeutics, cutting an estimated $2.32M.
  • RA Capital Management fully exited Dyne Therapeutics in Q3 2025, selling an estimated $92.5M.
  • RA Capital Management's ten largest holdings make up 64% of its $8.12B portfolio in Q3 2025.
  • RA Capital Management opened 15 new positions and closed 11 in Q3 2025.
  • RA Capital Management's portfolio value rose 37% quarter-over-quarter to $8.12B.

Based on RA Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.